Találati lista | Tudóstér

001-es BibID:	BIBFORM047569
Első szerző:	Benkő Ilona (orvos, farmakológus)
Cím:	Major and trace elements in mouse bone measured by surface and bulk sensitive methods / I. Benkő, I. Rajta, A. Csik, J. Tóth, K. Benkő, K. Géresi, É. Ungvári, B. Szabó, G. Sarkadi, B. Paripás, I. Takács, K. Tőkési
Dátum:	2012
Megjegyzések:	We present experimental investigations of the mouse bone in its original form and after calcination. We used various techniques, like scanning electron microscopy, secondary neutral mass spectroscopy, particle induced X-ray emission, and X-ray photoelectron spectroscopy. Among the major element's concentration profiles we also determined the observable trace elements of the mouse bone.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Nuclear Instruments & Methods in Physics Research. Section B. - 279 (2012), p. 223-226. -
További szerzők:	Rajta István (1970-) (fizikus) Csik Attila (1975-) (fizikus) Tóth József (fizikus) Benkő Klára Géresi Krisztina (1985-) (molekuláris biológus) Ungvári Éva (1986-) (molekuláris biológus) Szabó Boglárka Sarkadi Gréta Paripás Béla Takács István (belgyógyász) Tőkési Károly (1962-) (fizikus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM047593
Első szerző:	Benkő Klára
Cím:	Effect of Rosiglitazone on Radiation Damage in Bone Marrow Hemopoiesis / Klára Benkő, Éva Pintye, Boglárka Szabó, Krisztina Géresi, Attila Megyeri, Ilona Benkő
Dátum:	2008
Megjegyzések:	To study radiobiological effects and drugs, which can modify radiation injury, has an importance if we would like to avoid harmful effects of radiation due to emergency situations or treat patients with malignant diseases by radiotherapy. During the long treatment schedules patients may be treated by not only anticancer but many other drugs because of accompanying diseases. These drugs may also modify radiobiological effects. Rosiglitazone pre?treatment proved to be myeloprotective and accelerated recovery of 5?fluorouracil?damaged bone marrow in our previous experiments. Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects in radiation?damaged hemopoiesis. Bone marrow damage was precipitated by total body irradiation (TBI) using single increasing doses (2?10 Gy) of ??irradiation in groups of mice. Lethality was well correlated with damage in hemopoiesis measured by cellularity of bone marrow (LD50 values were 4.8 and 5.3 gray respectively). Rosiglitazone, an insulin?sensitizing drug, had no significant effect on bone marrow cellularity. Insulin resistance associated with obesity or diabetes mellitus type 2 is intensively growing among cancer patients requiring some kind of radiotherapy. Therefore it is important to know whether drugs used for their therapy can modify radiation effects.
ISBN:	978 0 7354 0611 7
Tárgyszavak:	Orvostudományok Elméleti orvostudományok előadáskivonat biological effects of radiation radiation therapy Monte Carlo methods DNA
Megjelenés:	Radiation Damage In Biomolecular Systems : Proceedings of the 5th International Conference : AIP Conference Proceedings volume 1080 / szerk. Karoly Tokesi, Bela Sulik. - p. 185-188. -
További szerzők:	Pintye Éva (1955-) (fizikus) Szabó Boglárka Géresi Krisztina (1985-) (molekuláris biológus) Megyeri Attila (1968-) (orvos) Benkő Ilona (1954-) (orvos, farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM020272
Első szerző:	Djazayeri, Katayoun
Cím:	Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil / Katayoun Djazayeria, Zoltán Szilvássy, Klára Benkő, Bernadett Rózsa, Boglárka Szabó, A. József Szentmiklósi, Ilona Benkő
Dátum:	2006
ISSN:	1043-6618
Megjegyzések:	AbstractHaematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg(-1)). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg(-1)) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban rosiglitazone myelotoxicity 5-fluorouracil
Megjelenés:	Pharmacological Research. - 53 : 2 (2006), p. 156-161. -
További szerzők:	Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Benkő Klára Rózsa Bernadett (1981-) (molekuláris biológus) Szabó Boglárka Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos) Benkő Ilona (1954-) (orvos, farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM038426
Első szerző:	Géresi Krisztina (molekuláris biológus)
Cím:	Toxicity of cytotoxic agents to granulocyte-macrophage progenitors is increased in obese Zucker and non-obese but insulin resistant Goto-Kakizaki rats / Géresi Krisztina, Benkő Klára, Szabó Boglárka, Megyeri Attila, Peitl Barna, Szilvássy Zoltán, Benkő Ilona
Dátum:	2012
ISSN:	0014-2999
Megjegyzések:	Increased risk of anticancer chemotherapy in seriously obese patients is known. Obesity may be among factors that predict treatment-related toxicity during chemotherapy. We investigated whether functional changes in granulopoiesis may also contribute to increased myelotoxicity in addition to the known alterations of pharmacokinetic parameters in obesity. Hemopoiesis - as measured by cellularity, frequency of granulocyte-macrophage progenitors (CFU-GM) and total CFU-GM content of the femoral bone marrow - did not differ in obese, insulin resistant Zucker rats compared with Wistar rats. Nevertheless increased sensitivity of their CFU-GM progenitor cells to cytotoxic drugs was found by culturing them in vitro in the presence of carboplatin, doxorubicin and 5-fluorouracil. All drugs were more toxic on CFU-GM progenitor cells of insulin resistant Zucker rats than on CFU-GM cells of the control strain. This might be based on metabolic disorders, at least in part, because we could demonstrate a similar increase in toxicity of the studied anticancer drugs to the CFU-GM progenitors originated from the non-obese but insulin resistant Goto-Kakizaki rats in the same dose ranges. After in vivo administration of rosiglitazone, an insulin sensitizer, the anticancer drug sensitivity of CFUGM progenitors of Goto-Kakizaki rats was decreased concurrently with improvement of insulin resistance. Although the increased treatment-related myelotoxicity and mortality are well-known among obese patients with malignant diseases, only the altered half lives, volumes of distribution and clearances of cytotoxic drugs are thought to be the underlying reasons. According to our knowledge the results presented here, are the first observations about an impaired granulopoiesis in obese animals.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	European Journal Of Pharmacology. - 696 : 1-3 (2012), p. 172-178. -
További szerzők:	Benkő Klára Szabó Boglárka Megyeri Attila (1968-) (orvos) Peitl Barna (1972-) (orvos, farmakológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Benkő Ilona (1954-) (orvos, farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: